Changing the tumor environment to overcome resistance to immune checkpoint therapy

Immune checkpoint inhibitors (ICIs) may reactivate the immune system's ability to target tumor cells, leading to promising clinical outcomes.

• Resistance to immune checkpoint therapy is associated with the specialized tumor microenvironment.
• Understanding how the tumor environment affects immunotherapy is critical for improving treatment effectiveness.
• Pre-clinical discoveries and ongoing clinical trials aim to address resistance to immune checkpoint inhibitors.

Simplified